Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 5-year average of 2.70%, near the low end of its 5-year range (0.00%–708.70%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 1.97%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
1.97%
DEBT TO ASSETS RATIO AVG 3Y
0.96%
DEBT TO ASSETS RATIO AVG 5Y
2.70%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Canton Strategic Holdings Inc
Market Cap
$183.94M
Debt to Assets Ratio
0.00%
TTM Avg
1.97%
3Y Avg
0.96%
5Y Avg
2.70%
Market Cap
$183.14M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$181.90M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$181.30M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$188.72M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$192.56M
Debt to Assets Ratio
0.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$174.88M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$173.76M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canton Strategic Holdings Inc (CNTN) | $183.94M | 0.00% | 1.97% | 0.96% | 2.70% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $183.14M | 0.00% | N/A | N/A | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $181.90M | 0.00% | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.30M | 0.00% | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $188.72M | 0.00% | N/A | N/A | N/A |
| RxSight, Inc. (RXST)vs › | $192.49M | 0.03% | N/A | N/A | N/A |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $192.56M | 0.18% | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $174.88M | 0.05% | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | 0.10% | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $173.39M | 0.26% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
15.70
Interest Coverage
-709.3x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 9.87% |
| 2025-03-31 | 16.34% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 3.57% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 7.00% |
| 2023-03-31 | 11.86% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 348.32% |
| 2021-09-30 | 519.37% |
| 2021-06-30 | 708.70% |
| 2021-03-31 | 2329.39% |
| 2020-12-31 | 627.67% |
